Neuphoria Therapeutics Net Income
| NEUP Stock | 4.05 0.02 0.49% |
As of the 17th of February 2026, Neuphoria Therapeutics secures the Mean Deviation of 1.99, standard deviation of 2.77, and Risk Adjusted Performance of (0.07). In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Neuphoria Therapeutics, as well as the relationship between them.
Neuphoria Therapeutics Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 0.527 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -332.7 M | -316 M | |
| Net Loss | -13.9 M | -14.6 M | |
| Net Loss | (0.31) | (0.33) | |
| Net Income Per E B T | 0.51 | 0.76 |
Neuphoria | Net Income | Build AI portfolio with Neuphoria Stock |
Evaluating Neuphoria Therapeutics's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Neuphoria Therapeutics's fundamental strength.
Latest Neuphoria Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Neuphoria Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Neuphoria Therapeutics financial statement analysis. It represents the amount of money remaining after all of Neuphoria Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Neuphoria Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Neuphoria Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (369.63 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Neuphoria Net Income Regression Statistics
| Arithmetic Mean | (10,275,419) | |
| Geometric Mean | 5,196,759 | |
| Coefficient Of Variation | (93.07) | |
| Mean Deviation | 8,046,868 | |
| Median | (8,646,819) | |
| Standard Deviation | 9,563,166 | |
| Sample Variance | 91.5T | |
| Range | 29.5M | |
| R-Value | (0.09) | |
| Mean Square Error | 96.8T | |
| R-Squared | 0.01 | |
| Significance | 0.73 | |
| Slope | (169,719) | |
| Total Sum of Squares | 1463.3T |
Neuphoria Net Income History
Other Fundumenentals of Neuphoria Therapeutics
Neuphoria Therapeutics Net Income component correlations
Neuphoria Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Neuphoria Therapeutics is extremely important. It helps to project a fair market value of Neuphoria Stock properly, considering its historical fundamentals such as Net Income. Since Neuphoria Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Neuphoria Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Neuphoria Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Can Biotechnology industry sustain growth momentum? Does Neuphoria have expansion opportunities? Factors like these will boost the valuation of Neuphoria Therapeutics. Anticipated expansion of Neuphoria directly elevates investor willingness to pay premium valuations. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Neuphoria Therapeutics demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Neuphoria Therapeutics's market price often diverges from its book value, the accounting figure shown on Neuphoria's balance sheet. Smart investors calculate Neuphoria Therapeutics' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Since Neuphoria Therapeutics' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Neuphoria Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Neuphoria Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Neuphoria Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Neuphoria Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Neuphoria Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Neuphoria Therapeutics.
| 11/19/2025 |
| 02/17/2026 |
If you would invest 0.00 in Neuphoria Therapeutics on November 19, 2025 and sell it all today you would earn a total of 0.00 from holding Neuphoria Therapeutics or generate 0.0% return on investment in Neuphoria Therapeutics over 90 days. Neuphoria Therapeutics is related to or competes with Inspira Technologies, Biomerica, Profusa Common, Aprea Therapeutics, Innovative Eyewear, Biocardia, and Alzamend Neuro. Neuphoria Therapeutics is entity of United States More
Neuphoria Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Neuphoria Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Neuphoria Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.12) | |||
| Maximum Drawdown | 14.8 | |||
| Value At Risk | (5.46) | |||
| Potential Upside | 3.67 |
Neuphoria Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Neuphoria Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Neuphoria Therapeutics' standard deviation. In reality, there are many statistical measures that can use Neuphoria Therapeutics historical prices to predict the future Neuphoria Therapeutics' volatility.| Risk Adjusted Performance | (0.07) | |||
| Jensen Alpha | (0.27) | |||
| Total Risk Alpha | (0.47) | |||
| Treynor Ratio | (1.83) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Neuphoria Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Neuphoria Therapeutics February 17, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.07) | |||
| Market Risk Adjusted Performance | (1.82) | |||
| Mean Deviation | 1.99 | |||
| Coefficient Of Variation | (1,109) | |||
| Standard Deviation | 2.77 | |||
| Variance | 7.69 | |||
| Information Ratio | (0.12) | |||
| Jensen Alpha | (0.27) | |||
| Total Risk Alpha | (0.47) | |||
| Treynor Ratio | (1.83) | |||
| Maximum Drawdown | 14.8 | |||
| Value At Risk | (5.46) | |||
| Potential Upside | 3.67 | |||
| Skewness | (0.47) | |||
| Kurtosis | 0.9718 |
Neuphoria Therapeutics Backtested Returns
Neuphoria Therapeutics has Sharpe Ratio of -0.0395, which conveys that the firm had a -0.0395 % return per unit of risk over the last 3 months. Neuphoria Therapeutics exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please verify Neuphoria Therapeutics' Standard Deviation of 2.77, risk adjusted performance of (0.07), and Mean Deviation of 1.99 to check out the risk estimate we provide. The company secures a Beta (Market Risk) of 0.14, which conveys not very significant fluctuations relative to the market. As returns on the market increase, Neuphoria Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Neuphoria Therapeutics is expected to be smaller as well. At this point, Neuphoria Therapeutics has a negative expected return of -0.11%. Please make sure to verify Neuphoria Therapeutics' maximum drawdown, daily balance of power, as well as the relationship between the Daily Balance Of Power and period momentum indicator , to decide if Neuphoria Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.41 |
Average predictability
Neuphoria Therapeutics has average predictability. Overlapping area represents the amount of predictability between Neuphoria Therapeutics time series from 19th of November 2025 to 3rd of January 2026 and 3rd of January 2026 to 17th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Neuphoria Therapeutics price movement. The serial correlation of 0.41 indicates that just about 41.0% of current Neuphoria Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.41 | |
| Spearman Rank Test | 0.04 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Neuphoria Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Neuphoria Therapeutics reported net income of (369.63 Million). This is 208.31% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 164.74% higher than that of the company.
Neuphoria Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Neuphoria Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Neuphoria Therapeutics could also be used in its relative valuation, which is a method of valuing Neuphoria Therapeutics by comparing valuation metrics of similar companies.Neuphoria Therapeutics is currently under evaluation in net income category among its peers.
Neuphoria Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Neuphoria Therapeutics from analyzing Neuphoria Therapeutics' financial statements. These drivers represent accounts that assess Neuphoria Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Neuphoria Therapeutics' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 9.5B | 4.8B | 1.2B | 11.5M | 10.4M | 9.9M | |
| Enterprise Value | 9.4B | 4.8B | 1.2B | (14.1B) | (12.7B) | (12.0B) |
Neuphoria Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Neuphoria Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Neuphoria Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Neuphoria Fundamentals
| Return On Equity | -0.64 | ||||
| Return On Asset | -0.0725 | ||||
| Profit Margin | (0.61) % | ||||
| Operating Margin | (0.19) % | ||||
| Current Valuation | 8.25 M | ||||
| Shares Outstanding | 5.38 M | ||||
| Shares Owned By Insiders | 7.74 % | ||||
| Shares Owned By Institutions | 48.07 % | ||||
| Number Of Shares Shorted | 36.99 K | ||||
| Price To Book | 1.74 X | ||||
| Price To Sales | 1.39 X | ||||
| Revenue | 23.95 M | ||||
| Gross Profit | 15.65 M | ||||
| EBITDA | (268.02 K) | ||||
| Net Income | (369.63 M) | ||||
| Total Debt | 116.31 M | ||||
| Book Value Per Share | 5.31 X | ||||
| Cash Flow From Operations | 77.23 M | ||||
| Short Ratio | 0.75 X | ||||
| Earnings Per Share | (4.02) X | ||||
| Target Price | 9.77 | ||||
| Market Capitalization | 21.78 M | ||||
| Total Asset | 28.59 B | ||||
| Retained Earnings | (178.35 B) | ||||
| Working Capital | 9.36 M | ||||
| Net Asset | 28.59 B |
About Neuphoria Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Neuphoria Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Neuphoria Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Neuphoria Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Neuphoria Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Neuphoria Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Neuphoria Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Neuphoria Stock
| 0.84 | VERA | Vera Therapeutics Sell-off Trend | PairCorr |
| 0.72 | EQ | Equillium | PairCorr |
| 0.72 | DRUG | Bright Minds Biosciences | PairCorr |
| 0.65 | DSGN | Design Therapeutics | PairCorr |
| 0.57 | DMAC | DiaMedica Therapeutics | PairCorr |
The ability to find closely correlated positions to Neuphoria Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Neuphoria Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Neuphoria Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Neuphoria Therapeutics to buy it.
The correlation of Neuphoria Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Neuphoria Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Neuphoria Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Neuphoria Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Neuphoria Stock Analysis
When running Neuphoria Therapeutics' price analysis, check to measure Neuphoria Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neuphoria Therapeutics is operating at the current time. Most of Neuphoria Therapeutics' value examination focuses on studying past and present price action to predict the probability of Neuphoria Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neuphoria Therapeutics' price. Additionally, you may evaluate how the addition of Neuphoria Therapeutics to your portfolios can decrease your overall portfolio volatility.